Sermorelin

Mechanism

Sermorelin is a truncated version of the natural growth hormone-releasing hormone (GHRH) your brain produces. It works by stimulating the pituitary gland to make and release more growth hormone naturally, preserving the body's normal feedback loops so you don't overshoot into excess GH levels. It is commonly used for age-related GH decline and supports improved body composition, sleep, and recovery.

Effects

## Endocrine/GH Axis [Tier 1 - Human Data, Previously FDA-Approved] - 29-amino-acid synthetic analog of endogenous GHRH(1-44), retaining full biological activity at the GHRH receptor - Stimulates pulsatile GH release from anterior pituitary somatotrophs via cAMP/PKA pathway activation - GH pulse amplitude increases 2-4x above baseline, with return to baseline within 1-2 hours (shorter half-life than CJC-1295 no DAC) - Preserves somatostatin negative feedback — cannot cause supraphysiological GH levels - Chronic administration restores youthful GH pulsatility patterns in elderly subjects (landmark study by Vittone et al.) - FDA-approved history (Geref Diagnostic) validates mechanism safety and efficacy ## Metabolic System [Tier 1 - Human Data] - IGF-1 elevation of 20-60% over 3-6 months of daily use - Improved body composition: reduced total body fat percentage (2-4% absolute reduction over 6-12 months) - Improved lipid profiles: modest reductions in LDL and total cholesterol - Improved insulin sensitivity in GH-deficient populations (GH restores hepatic insulin sensitivity at physiological levels) ## Musculoskeletal System [Tier 1 - Human Data] - Lean body mass preservation and modest increase (1-3 kg) over 6-12 months in clinical trials - Bone mineral density stabilization or modest improvement through IGF-1 mediated osteoblast activity - Enhanced collagen synthesis supporting tendon and ligament integrity ## Central Nervous System [Tier 2 - Clinical Observation] - Improved sleep quality — especially deep slow-wave sleep where GH release naturally peaks - Cognitive improvements reported in aging populations (GH/IGF-1 supports neuroplasticity) - Improved mood and sense of well-being commonly reported ## Integumentary System [Tier 2 - Clinical Observation] - Skin thickness and elasticity improvement over 3-6 months - Reduced appearance of fine wrinkles through dermal collagen stimulation - Improved wound healing ## Immune System [Tier 2 - Mechanistic/Observational] - GH/IGF-1 axis restoration supports age-related immune decline (immunosenescence) - Improved thymic output and T-cell diversity theorized with sustained GH optimization

Practitioner Guide

## Clinical Positioning Sermorelin is the original GHRH analog — the one with FDA history and the longest clinical track record. It has been largely superseded by CJC-1295 no DAC in most peptide clinics due to CJC's longer half-life and more robust GH pulse, but sermorelin remains a legitimate option with certain advantages. ## Sermorelin vs. CJC-1295 no DAC - Sermorelin: shorter half-life (~10-15 min vs. ~30 min), slightly weaker GH pulse, but has actual FDA approval history and extensive human safety data - CJC-1295 no DAC: more potent per dose, longer pulse, but no FDA history - Some clinics prefer sermorelin for conservative patients or those new to peptide therapy because of its regulatory pedigree - The two should NOT be combined (both compete for the same GHRH receptor) ## Dosing Protocols ### Standard Protocol - Sermorelin: 200-300mcg SC at bedtime, fasted - With ipamorelin: 200mcg sermorelin + 200mcg ipamorelin in same syringe (synergy applies same as CJC/IPA) - Nightly or 5 on/2 off ### Pediatric/Adolescent (Under Endocrinologist Supervision) - Sermorelin was used in children with GH deficiency when Geref was available - Doses ranged from 200-1000mcg daily depending on weight and response - Advantage over exogenous GH: preserves pituitary function and natural feedback ### Transition/Cost Protocol - Some patients start with sermorelin (lower cost, established safety) and switch to CJC-1295 no DAC if they want a stronger GH response - Others alternate: 3 months sermorelin, 3 months CJC-1295 no DAC ## What to Expect - Similar timeline to CJC-1295/ipamorelin but effects may be slightly more subtle due to shorter GH pulse - Sleep improvement: 1-2 weeks - Recovery improvement: 2-4 weeks - Body composition: 2-4 months - Full benefits: 4-6 months ## Blood Work Same protocol as CJC-1295 no DAC: IGF-1 at baseline, 6-8 weeks, and every 3-6 months ## Side Effects - Injection site irritation (more common than CJC, possibly due to histamine release at injection site) - Facial flushing (transient, within minutes of injection, harmless) - Headache (rare) - Overall very well-tolerated

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  GHRH analogues stimulate GH release and elevate IGF-1 levels. IGF-1 promotes cell proliferation and may accelerate tumor growth and progression.
  Action: Do not use in patients with any active cancer diagnosis. Cancer survivors should obtain oncologist clearance.
• hard stop — Pregnancy
  No adequate human safety data during pregnancy. GH/IGF-1 elevation poses theoretical risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use. Exogenous GH stimulation may disrupt normal growth and development.
  Action: Do not provide peptide protocols to individuals under 18. Refer to pediatric endocrinologist.
• requires physician — Diabetes
  GHRH-mediated GH elevation antagonizes insulin action and may worsen glycemic control in diabetic patients.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Diabetes medication adjustment may be needed.

Stacks featuring this peptide

Research Summary

## Tier 1 — Human Clinical Data (FDA-Approved History) - Sermorelin (as Geref) was FDA-approved for diagnostic evaluation of pituitary GH secretion and for treatment of GH deficiency - Vittone et al.: 6-month sermorelin trial in healthy elderly showed restoration of youthful GH pulse frequency and amplitude - Multiple Phase II/III trials in GH-deficient children showed effective restoration of growth velocity - Long-term safety data from years of clinical use: no significant safety signals - Withdrawn from market for commercial reasons (not safety concerns) by manufacturer ## Tier 2 — Clinical Observation - Widely prescribed in anti-aging clinics for 15+ years - Clinical consensus: effective but less potent than CJC-1295 no DAC per injection - Combination with ipamorelin produces comparable results to CJC/IPA in clinical practice - Well-tolerated with minimal side effects; injection site flushing is the most common complaint ## Tier 3 — Preclinical - Full GHRH receptor pharmacology well-characterized - Truncation from 44 to 29 amino acids retains 100% receptor binding and activation - Susceptible to DPP-IV degradation (position 2 alanine) — the limitation that CJC-1295 addressed with amino acid substitutions ## Evidence Gaps - No modern Phase III trials with contemporary endpoints - Head-to-head vs. CJC-1295 no DAC never formally studied - Long-term outcomes (cancer, cardiovascular) not prospectively tracked